NASDAQ NMS - GLOBAL MARKET · DFTX
-4.25% · -$1.91 · Vol 1.7M
Market closed · last close 4:00 PM ET · price as of 19:53:17 ET
Definium Therapeutics Inc

Definium Therapeutics Inc

Pharmaceuticals
$43.00
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
DFTX
Definium Therapeutics Inc
Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

47/ 100
Veridion Score
NEUTRAL · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DFTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DFTX catalysts
About Definium Therapeutics Inc
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Listed since
2020
Employees
106
Country
US

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$44.46
Day high
$44.46
Day low
$41.25
Previous close
$44.91
52W high
$48.45
-11.24% from high
52W low
$15.05
84% of range
Market cap
$6B
EPS
$-4.3000
Beta
0.57
Shares out
134.4M
Volume
1.7M
0.85× rel vol
Avg volume
2M
VWAP
$43.16
Price history computed in-house
1W
-6.88%
1M
-0.39%
3M
+82.84%
SMA 50 $42.01 · above
SMA 200 Not reported · Not reported
52W position 84%

DFTX overview

Veridion Score
47
Registered · 2026-08-24
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DFTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DFTX Form 4 filings
Public disclosures

Congress activity in DFTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DFTX in the cached public ledger.

Federal contracts

DFTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DFTX in this window.
Lobbying spend

DFTX lobbying filings, year to date.

Registered lobbying filings matched to Definium Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DFTX in this window.
Loading news for DFTX
Analyst ratings
Sovereign unlock shows live analyst consensus for DFTX.
Options
Sovereign unlock shows live options positioning for DFTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.